CIK 0001674632 · Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
Beta Bionics, Inc.
Sign in to watch- Ticker
- BBNX
- Exchange
- Nasdaq
- Industry
- Surgical & Medical Instruments & Apparatus
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 475386878
- Phone
- 949-427-7785
- Business address
- 11 HUGHES, IRVINE, CA, 92618
- Former names
- Beta Bionics, Inc
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $3,133,054
- in 19 filings, $2.4M under 10b5-1 plans
Net −$3,133,054. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-11-09 | Feider Stephen Chief Financial Officer | Option exercise 10b5-1 | +744 | $5.10 | $4K | 160,122 |
| 2026-11-09 | Feider Stephen Chief Financial Officer | Sale 10b5-1 | −744 | $17.00 | $13K | 159,378 |
| 2026-11-09 | Feider Stephen Chief Financial Officer | Option exercise · Employee Stock Option (right to buy) 10b5-1 | −744 | 38,569 | ||
| 2026-11-05 | Feider Stephen Chief Financial Officer | Option exercise 10b5-1 | +382 | $5.10 | $2K | 159,760 |
| 2026-11-05 | Feider Stephen Chief Financial Officer | Sale 10b5-1 | −382 | $17.04 | $7K | 159,378 |
| 2026-11-05 | Feider Stephen Chief Financial Officer | Option exercise · Employee Stock Option (right to buy) 10b5-1 | −382 | 39,313 | ||
| 2026-11-02 | Hopman Mark Chief Commercial Officer | Sale 10b5-1 | −370 | $16.90 | $6K | 54,143 |
| 2026-10-27 | Mensinger Mike Chief Product Officer | Sale 10b5-1 | −2,650 | $22.00 | $58K | 174,740 |
| 2026-10-26 | Hopman Mark Chief Commercial Officer | Sale 10b5-1 | −821 | $20.00 | $16K | 54,513 |
| 2026-10-14 | Hopman Mark Chief Commercial Officer | Sale | −775 | $17.35 | $13K | 55,334 |
| 2026-10-01 | Hopman Mark Chief Commercial Officer | Sale | −370 | $18.96 | $7K | 56,109 |
| 2026-09-22 | Jones Christy Director | Sale 10b5-1 | −6,430 | $23.00 | $148K | 19,564 |
| 2026-09-16 | Mensinger Mike Chief Product Officer | Sale 10b5-1 | −2,650 | $22.00 | $58K | 177,390 |
| 2026-09-16 | Hopman Mark Chief Commercial Officer | Sale 10b5-1 | −30,779 | $20.13 | $620K | 56,479 |
| 2026-09-14 | Hopman Mark Chief Commercial Officer | Sale 10b5-1 | −775 | $15.52 | $12K | 86,382 |
| 2026-09-09 | Hopman Mark Chief Commercial Officer | Sale 10b5-1 | −35,994 | $18.46 | $665K | 88,033 |
| 2026-09-09 | Hopman Mark Chief Commercial Officer | Sale 10b5-1 | −36,870 | $18.46 | $681K | 87,157 |
| 2026-09-03 | Saint Sean President & CEO | Sale 10b5-1 | −5,641 | $20.08 | $113K | 398,429 |
| 2026-09-02 | Russell Steven Jon Chief Medical Officer | Sale | −4,221 | $19.11 | $81K | 169,628 |
| 2026-09-02 | Saint Sean President & CEO | Sale | −16,867 | $19.11 | $322K | 404,070 |
Page 1 of 11 · 207 trades